Aurobindo Pharma's US branch obtained approval from the U.S. Federal Trade Commission (FTC) to move forward with its $250 million acquisition of Lannett Company LLC.

The acquisition, which will be done on a cash-free, debt-free basis and includes normalized working capital, is anticipated to finalize by the end of June 2026. The company stated in a regulatory filing that the transaction is anticipated to be instantly beneficial to Aurobindo Group’s earnings per share.

The pharmaceutical giant stated that the acquisition of Lannett is expected to produce significant cost savings, SG&A synergies, and operational integration benefits. It will further enrich Aurobindo Pharma's offerings with a distinct array of complex generics and controlled substances, promoting long-term sustainable growth.

"This purchase signifies a very attractive strategic and financial chance for Aurobindo USA," stated Swami S. Iyer, CEO of Aurobindo Pharma USA.

Also Read: Inventions from Bengaluru that are Serving Tech Prowess, Societal Good

"It boosts our revenue growth, fortifies our US manufacturing capabilities, and improves our standing in complex, non-opioid regulated substances. We believe it will provide instant earnings growth while generating long-term benefits for our investors via operational efficiencies and pipeline development,"adds Swami.

Lannett is a generic pharmaceutical firm located in Pennsylvania, focusing on the creation and marketing of a varied range of complex, non-opioid controlled drugs.

Also Read: AI Appreciation Day: From Innovation to Transformation

The acquisition will greatly enhance Aurobindo USA’s product range in this segment and include a manufacturing site in the US within its network. Lannett’s production facility in Seymour, Indiana, can increase output to about 4 billion doses each year, thereby enhancing Aurobindo USA’s local manufacturing presence. This increased capability corresponds with U.S. policy goals focused on strengthening supply chain resilience and boosting domestic pharmaceutical manufacturing.

Also Read: Karnataka to Become Quantum Capital of Asia Soon

Tim Crew, Lannett Company’s CEO says, “We are delighted to be joining forces with Aurobindo. As one of the nation’s oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. Aurobindo’s market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere."